{"longTitle":"Cell Line Gene Expression (Neve et al. Cancer Cell 2006)","cohort":"Breast Cancer Cell Lines (Neve 2006)","url":"http://www.ncbi.nlm.nih.gov/pubmed/17157791","probeMap":"probeMap/affyU133_ucscGenomeBrowser_hg18.probeMap","dataSubType":"gene expression","citation":"Cancer Cell. 2006 Dec;10(6):515-27.","label":"Neve Cell Line gene expression","articletitle":"A collection of breast cancer cell lines for the study of functionally distinct cancer subtypes.","tags":["cell lines","breast cancer"],"anatomical_origin":["Breast"],"name":"ucsfNeve_public/ucsfNeveExp_genomicMatrix","dataproducer":"Neve RM et. al.","sample_type":["cell line"],"type":"genomicMatrix","version":"2011-11-01","gdata_tags":["transcription","mRNA"],"primary_disease":"breast cancer","description":"Recent studies suggest that thousands of genes may contribute to breast cancer pathophysiologies when deregulated by genomic or epigenomic events. Here, we describe a model \"system\" to appraise the functional contributions of these genes to breast cancer subsets. In general, the recurrent genomic and transcriptional characteristics of 51 breast cancer cell lines mirror those of 145 primary breast tumors, although some significant differences are documented. The cell lines that comprise the system also exhibit the substantial genomic, transcriptional, and biological heterogeneity found in primary tumors. We show, using Trastuzumab (Herceptin) monotherapy as an example, that the system can be used to identify molecular features that predict or indicate response to targeted therapies or other physiological perturbations."}

Cell Line Gene Expression (Neve et al. Cancer Cell 2006)

{"cohort":"Breast Cancer Cell Lines (Neve 2006)","url":"http://www.ncbi.nlm.nih.gov/pubmed/17157791","dataSubType":"phenotype","label":"Phenotypes","tags":["cancer"],"name":"ucsfNeve_public/ucsfNeve_public_clinicalMatrix","clinicalfeature":"ucsfNeve_public/ucsfNeve_public_clinicalFeature","type":"clinicalMatrix","version":"2011-11-11"}